Brought to you by 
Cell Genesys subsidiary Abgenix nets $21.39 in IPO
13 Jul 1999
Executive Summary
Cell Genesys subsidiary Abgenix (monoclonal antibodies) completed its IPO, netting $21.39mm on the sale of 2.875mm common shares at $8 each. The per share price is lower than the $10-12 hoped for when the company initially filed.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cell Genesys subsidiary Abgenix nets $21.39 in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice